Pragmatic Guide to Assessing Real Option Value for Medical Technologies
A structured approach to estimate the additional value of a medical technology that comes from future opportunities, such as learning over time, potential improvements, or follow-on innovations, which traditional cost-effectiveness analyses often miss.
At a glance
Use when
Assessing novel technologies with high uncertainty and potential for future improvements, when early adoption could enable learning or catalyze innovation, or when traditional cost-effectiveness analysis underestimates long-term value.
Avoid when
When data on future scenarios are extremely limited, when decisions are irreversible or inflexible, or when the technology has a well-understood, static pathway with little innovation potential.
Inputs
Clinical and economic uncertainty parameters, time horizons, probabilities of future events (e.g., technological improvements, regulatory changes), cost of investment, discount rates, potential future scenarios.
Outputs
Estimated real option value, incremental value over traditional cost-effectiveness results, qualitative insights into strategic flexibility.
How it works
This method provides a stepwise framework for incorporating real options analysis (ROA) into health technology assessment, enabling evaluators to quantify the value of flexibility and future learning associated with adopting a new medical technology. It adapts financial real options concepts to the healthcare context, guiding users through identifying option-like characteristics, modeling uncertainty, and estimating option value using decision-analytic techniques.
- HTA domains
- Costs & Economic Evaluation, Organisational aspects, Aspects Beyond HTA
- Assumptions
- Future events are uncertain but can be modeled probabilistically; decision makers can adapt strategies over time; early adoption may enable learning or trigger innovation; market and regulatory conditions allow for flexible decision-making.
- Strengths
- Captures value not reflected in standard HTA methods; supports strategic, forward-looking decisions; accounts for dynamic innovation pathways; enhances transparency in valuing uncertainty and flexibility.
- Limitations
- Requires complex modeling and subjective inputs; data on future probabilities and innovation pathways may be scarce; results can be sensitive to assumptions; not widely adopted in routine HTA practice.
- Also known as
- Real Option Value Assessment Guide, ROV method for medical technologies
Questions this answers
- › What is the potential future value of a medical technology beyond its current clinical and economic performance?
- › How can future learning and innovation be incorporated into value assessment?
- › What is the value of delaying, adapting, or scaling up adoption based on emerging evidence?
- › How does uncertainty in future outcomes affect the value of a technology?
- › When is it valuable to adopt a technology early despite limited evidence?
- › How can decision makers account for follow-on innovations triggered by initial adoption?
References & sources
Similar by meaning
Beta record. Based on the original catalogue summary; primary-source enrichment pending.